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Abstract: Background Drug resistance threatens global tuberculosis control. We aimed to examine mor-
tality in patients with tuberculosis from high-burden countries, according to concordance or discordance
of results from drug susceptibility testing done locally and whole-genome sequencing (WGS). Methods
In this multicentre cohort study, we collected pulmonary Mycobacterium tuberculosis isolates and clin-
ical data from individuals with tuberculosis from antiretroviral therapy programmes and tuberculosis
clinics in Côte d’Ivoire, Democratic Republic of the Congo, Kenya, Nigeria, Peru, South Africa, and
Thailand, stratified by HIV status and drug resistance. Sites tested drug susceptibility using routinely
available methods. WGS was done on Illumina HiSeq 2500 in the USA and Switzerland, and TBprofiler
was used to analyse the genomes. We included individuals aged 16 years or older with pulmonary tu-
berculosis (bacteriologically confirmed or clinically diagnosed). We analysed mortality in multivariable
logistic regression models adjusted for sex, age, HIV status, history of tuberculosis, and sputum positiv-
ity. Findings Between Sept 1, 2014, and July 4, 2016, of 634 patients included in our previous analysis,
we included 582 patients with tuberculosis (median age 33 years [IQR 27–43], 225 [39%] women, and 247
[42%] HIV-positive). Based on WGS, 339 (58%) isolates were pan-susceptible, 35 (6%) monoresistant,
146 (25%) multidrug-resistant, and 24 (4%) pre-extensively drug-resistant (pre-XDR) or XDR. The anal-
ysis of mortality was based on 530 patients; 63 (12%) died and 77 (15%) patients received inappropriate
treatment. Mortality ranged from 6% (18 of 310) in patients with pan-susceptible tuberculosis to 39%
(nine of 23) in patients with pre-XDR or XDR tuberculosis. The adjusted odds ratio for mortality was
4·92 (95% CI 2·47–9·78) among undertreated patients, compared with appropriately treated patients.
Interpretation In seven countries with a high burden of tuberculosis, we observed discrepancies between
drug resistance patterns obtained locally and WGS. The underdiagnosis of drug resistance resulted in
inappropriate treatment and higher mortality. WGS can provide accurate and detailed drug resistance
information required to improve the outcomes of drug-resistant tuberculosis in high-burden settings. Our
results support WHO’s call for point-of-care tests based on WGS. Funding National Institutes of Allergy
and Infectious Diseases, Swiss National Science Foundation, and Swiss National Center for Mycobacteria.
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Summary
Background Drug resistance threatens global tuberculosis control. We aimed to examine mortality in patients with 
tuberculosis from high-burden countries, according to concordance or discordance of results from drug susceptibility 
testing done locally and whole-genome sequencing (WGS).
Methods In this multicentre cohort study, we collected pulmonary Mycobacterium tuberculosis isolates and clinical data 
from individuals with tuberculosis from antiretroviral therapy programmes and tuberculosis clinics in Côte d’Ivoire, 
Democratic Republic of the Congo, Kenya, Nigeria, Peru, South Africa, and Thailand, stratified by HIV status and 
drug resistance. Sites tested drug susceptibility using routinely available methods. WGS was done on Illumina HiSeq 
2500 in the USA and Switzerland, and TBprofiler was used to analyse the genomes. We included individuals aged 
16 years or older with pulmonary tuberculosis (bacteriologically confirmed or clinically diagnosed). We analysed 
mortality in multivariable logistic regression models adjusted for sex, age, HIV status, history of tuberculosis, and 
sputum positivity.
Findings Between Sept 1, 2014, and July 4, 2016, of 634 patients included in our previous analysis, we included 
582 patients with tuberculosis (median age 33 years [IQR 27–43], 225 [39%] women, and 247 [42%] HIV-positive). 
Based on WGS, 339 (58%) isolates were pan-susceptible, 35 (6%) monoresistant, 146 (25%) multidrug-resistant, and 
24 (4%) pre-extensively drug-resistant (pre-XDR) or XDR. The analysis of mortality was based on 530 patients; 
63 (12%) died and 77 (15%) patients received inappropriate treatment. Mortality ranged from 6% (18 of 310) in patients 
with pan-susceptible tuberculosis to 39% (nine of 23) in patients with pre-XDR or XDR tuberculosis. The adjusted 
odds ratio for mortality was 4·92 (95% CI 2·47–9·78) among undertreated patients, compared with appropriately 
treated patients.
Interpretation In seven countries with a high burden of tuberculosis, we observed discrepancies between drug 
resistance patterns obtained locally and WGS. The underdiagnosis of drug resistance resulted in inappropriate 
treatment and higher mortality. WGS can provide accurate and detailed drug resistance information required to 
improve the outcomes of drug-resistant tuberculosis in high-burden settings. Our results support WHO’s call for 
point-of-care tests based on WGS.
Funding National Institutes of Allergy and Infectious Diseases, Swiss National Science Foundation, and Swiss 
National Center for Mycobacteria.
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Introduction
Tuberculosis is caused by bacteria of the Mycobacterium 
tuberculosis complex and is the leading cause of death by 
a single infectious agent worldwide.1 In 2019, ten million 
people were estimated to have developed active 
tuberculosis, of whom 8% also had HIV. In the same 
year, around 1·2 million people died from tuberculosis, 
including 208 000 people with HIV.1 Tuberculosis 
accounts for approximately 40% of HIV and AIDS-related 
adult deaths, and half of these remain undiagnosed.2
The emergence of drug-resistant M tuberculosis strains 
threatens tuberculosis control. In 2019, 3% of new 
tuberculosis cases worldwide were estimated to be 
multidrug-resistant (MDR) tuberculosis, and 18% of 
individuals who had been previously treated had MDR 
tuberculosis.1 People with HIV are at greater risk of 
acquiring MDR tuberculosis than people who are 
HIV-negative.3 Also, treatment outcomes in people with 
HIV and MDR tuberculosis are worse than among HIV-
negative patients with MDR tuberculosis.3 Pre-extensively 
drug-resistant (pre-XDR) or XDR tuberculosis poses 
additional challenges for treatment and control of the 
disease.4 Strategies to control and prevent drug-resistant 
tuberculosis include surveillance, rapid drug susceptibility 
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testing, and ensuring the completion of an appropriate 
treatment regimen. The limited access to detailed 
drug susceptibility testing and effective second-line 
anti-tuberculosis drugs, insufficient adherence and drug 
dosages, and comorbidities challenge the management of 
drug-resistant tuberculosis in low-income and middle-
income countries.2,5–7
The present study is part of a research programme 
investigating drug-resistant tuberculosis of the Inter-
national epidemiology Databases to Evaluate AIDS.8 In a 
previous analysis, we compared the results of drug 
susceptibility testing from high-burden countries in 
Africa, Asia, and Latin America with phenotypic drug 
susceptibility testing results from the Swiss National 
Center for Mycobacteria.9 We found that the accuracy of 
testing done at participating sites was moderate, and 
that discordant results and inappropriate treatment 
were associated with increased mortality. The Swiss 
reference laboratory tested drug resistance to six drugs 
only: isoniazid, rifampicin, pyrazinamide, ethambutol, 
amikacin, and moxifloxacin. Therefore, other resistances 
could have been missed, including resistance to 
streptomycin, kanamycin, ethio namide, levofloxacin, or 
newer drugs.
Whole-genome sequencing (WGS) can simultaneously 
provide information on resistance to first-line and 
second-line drugs, for which drug-resistance-conferring 
mutations are known. WGS has the potential to over-
come many of the limitations of conventional drug 
suscepti bility testing with higher throughput.10 We and 
others showed that drug susceptibility predicted from 
M tuberculosis genomes correlates with phenotypic drug 
susceptibility testing.11,12 WHO recommends WGS for 
drug resistance surveillance and is evaluating sequencing 
technologies for routine drug susceptibility testing.1,13 
Here, we aimed to compare the drug resistance patterns 
routinely obtained in seven countries with a high 
tuberculosis burden with the results from WGS, and 
examined the mortality associated with discordant 
resistance profiles using WGS as the reference.
Methods
Study design and participants
We did a multicentre cohort study. As described in detail 
elsewhere,9 we recruited patients from antiretroviral 
therapy programmes and tuberculosis clinics in their 
corresponding catchment areas in Côte d’Ivoire, 
Democratic Republic of the Congo, Kenya, Nigeria, 
Peru, South Africa, and Thailand. In South Africa, we 
used strain collections held at the University of Cape 
Town (Cape Town, South Africa). All patients had 
bacterio logically confirmed, or clinically diagnosed 
tuberculosis. We included individuals aged 16 years or 
older with pulmonary tuberculosis. We excluded 
patients for whom no viable isolate was available, 
patients with extrapulmonary tuberculosis only, patients 
with missing data that were necessary for the analyses, 
and patients for whom the M tuberculosis genome could 
Research in context
Evidence before this study
Drug-resistant tuberculosis, in particular multidrug-resistant 
tuberculosis and extensively drug-resistant tuberculosis, is 
threatening the control of tuberculosis worldwide. WHO has 
highlighted the need to improve drug susceptibility testing and 
treatment of drug-resistant tuberculosis, particularly in 
countries with a high burden of tuberculosis. Whole-genome 
sequencing (WGS) has the potential to provide resistance 
profiles for all first-line and second-line anti-tuberculosis drugs 
and is increasingly replacing other drug resistance testing 
methods. Yet, the potential of WGS in routine clinical care has 
not been shown in low-income and middle-income countries, 
where the burden of drug-resistant tuberculosis is high. We 
searched PubMed for systematic reviews and original research 
articles published in any language up to June 29, 2020. We 
combined terms for “tuberculosis”, “whole-genome 
sequencing”, and “mortality”. Several validation studies showed 
that WGS could accurately predict drug resistance; however, we 
could not find any study showing the potential benefit of WGS-
based drug resistance testing on survival.
Added value of this study
In this study, we compared drug resistance profiles from WGS 
with routine drug susceptibility test results in seven countries 
across three continents with a high tuberculosis burden and 
assessed the effect of undiagnosed drug resistance on mortality. 
Results from WGS and routine drug susceptibility testing were 
discordant in 22% of patients. Resistance to isoniazid and 
rifampicin was accurately identified at local clinics, whereas 
resistance to ethambutol, pyrazinamide, and second-line drugs 
was rarely tested locally. Mortality ranged from 6% in patients 
with pan-susceptible tuberculosis who were appropriately 
treated to 32% in patients with drug-resistant tuberculosis who 
were undertreated.
Implications of all the available evidence
Routine drug susceptibility testing in resource-limited settings 
with a high tuberculosis burden is often insufficient to inform 
the prescription of the most effective treatment regimen, 
which in turn contributes to higher mortality. Our results 
support the implementation of point-of-care protocols for 
WGS, ideally directly from sputum to obtain comprehensive 
drug resistance profiles and facilitate the initiation of 
personalised and effective treatment regimens.
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not be sequenced (appendix p 2). Recruitment was 
stratified by HIV status and drug resistance as defined 
at local clinics. We collected demographic and clinical 
characteristics of participants using a standardised 
questionnaire. M tuberculosis isolates were subcultured 
at the recruitment sites.
The Cantonal Ethics Committee in Bern, Switzerland, 
and local institutional review boards approved the study. 
Written informed consent was obtained at all sites, 
except in South Africa, where consent was not required 
for the use of archived samples.
Procedures
The local laboratories tested molecular or phenotypic drug 
susceptibility according to routine procedures. DNA was 
extracted from isolates using standard protocols.14 Libraries 
were prepared using the Illumina Nextera XT kit (Illumina, 
San Diego, CA, USA) and sequenced on Illumina 
HiSeq 2500 at the Department of Biosystems Science and 
Engineering of the Swiss Federal Institute of Technology in 
Basel, Switzerland and the Broad Institute in Cambridge, 
MA, USA. Sequences had 101, 138, or 151 bp paired-end 
reads. After Illumina adaptors were clipped and low-quality 
reads trimmed with Trimmomatic, version 0.38, reads 
shorter than 36 bp were excluded. The minimum read 
depth at each position was 10 × in 99% of the genome 
(IQR 99–99, range 77–100; seven genomes were less 
than 90%). BCFtools, version 1.11 mpileup was used to map 
the reads to the H37Rv reference genome. We included 
reads with a minimum mapping quality of eight. We 
screened one isolate per patient for anti-tuberculosis drug 
resis tance mutations using the TBprofiler, version 2.8.2 
pipeline.10,15 The pipeline aligns reads to the reference 
genome using BWA, version 0.7.17 and calls variants 
with SAMtools, version 1.9.10,16–18 The variants were then 
compared to a drug resistance database. Single-nucleotide 
polymorphisms, insertions, and deletions responsible for 
resistance to 19 anti-tuberculosis drugs were identified:10,15,19 
streptomycin, para-aminosalicylic acid, isoniazid, pyra-
zinamide, cycloserine, kanamycin, ethio namide, etham-
butol, amikacin, rifampicin, capreo mycin, ofloxacin, 
cipro floxacin, moxafloxacin, levofloxacin, linezolid, 
bedaquiline, clofazimine, and delamanid. A coverage of 
ten reads was needed to call a polymorphism. We 
considered all drug resistance alleles with a variant 
frequency equal to or higher than 90%.
WHO defines monoresistance as resistance to 
one of the first-line drugs (ie, isoniazid, pyrazinamide, 
ethambutol, and rifampicin).1,13 MDR tuberculosis is 
defined as resistance to both isoniazid and rifampicin. 
Pre-XDR tuberculosis is defined as resistance to 
isoniazid and rifampicin plus fluoroquinolones or one 
of the three second-line injectable drugs (ie, amikacin, 
ciprofloxacin, or kanamycin). XDR tuberculosis is 
defined as drug resistance against isoniazid, rifampicin, 
fluoroquinolones, and at least one of the three second-line 
injectable drugs.
We compared the drug resistance profiles obtained at sites 
using routine drug susceptibility testing to drug resistance 
patterns obtained from whole-genome sequences. We 
considered any drug resistance obtained from the tests that a 
patient underwent locally. Drug resistance profiles were 
defined as concordant or discordant according to the 
resistance categories defined by WHO.1 Discordant results 
were further categorised into discordant results potentially 
leading to undertreatment, or potentially leading to 
overtreatment (appendix p 6).1,13 Discordances with no clear 
implications for treatment were defined as other discor-
dances. We assessed the appropriateness of prescribed anti-
tuberculosis treatment according to WHO guidelines 
(appendix p 7).1,13 Effective drugs were defined as drugs to 
which no drug-resistance-conferring mutations were 
observed in WGS (appendix p 8). The prescription of less 
than three effective drugs was defined as under treatment, 
except for patients with isoniazid-resistant or rifampicin-
resistant isolates. In these patients, a regimen comprising 
fewer than four effective drugs was considered as under-
treatment, according to WHO guidelines. Over treatment 
included second-line drugs given to patients for whom 
first-line regimens would have been appropriate. The 
classification of regimens is shown in the appendix (p 11).
Statistical analysis
We used descriptive statistics for patient characte ristics 
by levels of drug resistance based on WGS. We com-
pared the following drug resistance categories: pan-
susceptible tuber culosis, monoresistant tuberculosis 
(any mono resistance), MDR tuberculosis, pre-XDR or 
XDR tuberculosis, any isoniazid-resistant tuberculosis 
(including isoniazid-monoresistant, MDR, and pre-XDR 
or XDR tuberculosis), any rifa mpicin-resistant tuber-
culosis (including rifampicin-monoresistant, MDR, and 
pre-XDR or XDR tuber culosis). Patients with missing 
data for treatment regimen, treatment outcome, ongoing 
treatment, or sputum microscopy were excluded from 
the analysis of mortality.
Four logistic regression models were calculated to assess 
the effects of: any drug resistance; drug resistance 
categories; discordant diagnoses; and treatment appro-
priate ness on mortality. Logistic regression models were 
adjusted for sex, age, HIV status, history of tuberculosis, 
and sputum positivity. The country of origin was included 
as a random effect on the intercept.20 We did three 
sensitivity analyses. First, we repeated all logistic regression 
analyses after restricting the data to drug resistances that 
could be diagnosed with the locally available tests. We 
thus excluded drug resistances that were missed due to 
unavailable testing methods. Second, we repeated the 
logistic regression for mortality by treatment appro-
priateness, excluding patients with pre-XDR or XDR 
tuberculosis. Third, we examined the effect of different 
variant frequency cutoffs on each logistic regression 
(≥0% and 100%). All analyses were done in R, version 3.6.1, 
or Python, version 3.7.6.21,22
For the pipeline see 
https://github.com/jodyphelan/
TBProfiler
For the database see https://
github.com/jodyphelan/tbdb
Articles
e323 www.thelancet.com/microbe   Vol 2 July 2021
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Between Sept 1, 2014, and July 4, 2016, of the 634 patients 
included in our previous analysis,9 we were unable to 
sequence 52 (8%) isolates due to poor bacterial growth, 
Pan-susceptible Any 
resistance
p value Monoresistance Polyresistance





Total 339 243 ·· 35 8 2 1 24 208 146 24 38
Sex ·· ·· 0·99 ·· ·· ·· ·· ·· ·· ·· ·· ··
Women 131 (39%) 94 (39%) ·· 10 (29%) 3 (38%) 0 (0%) 1 (100%) 6 (25%) 84 (40%) 56 (38%) 13 (54%) 15 (39%)
Men 208 (61%) 149 (61%) ·· 25 (71%) 5 (63%) 2 (100%) 0 18 (75%) 124 (60%) 90 (62%) 11 (46%) 23 (61%)
Age, years ·· ·· 0·0067 ·· ·· ·· ·· ·· ·· ··
At diagnosis 35 (28–45) 32 (25–40) ·· 32 (25–40) 40 (31–49) 26 (25–28) 36 (36–36) 29 (25–39) 32 (26–40) 31 (25–39) 30 (25–34) 36 (29–44)
HIV status ·· ·· <0·0001 ·· ·· ·· ·· ·· ·· ·· ·· ··
HIV-negative 169 (50%) 166 (68%) ·· 23 (66%) 7 (88%) 1 (50%) 0 15 (63%) 143 (69%) 103 (71%) 14 (58%) 26 (68%)
HIV-positive 170 (50%) 77 (32%) ·· 12 (34%) 1 (13%) 1 (50%) 1 (100%) 9 (38%) 65 (31%) 43 (29%) 10 (42%) 12 (32%)
Mycobacterium 
tuberculosis lineage
·· ·· 0·039 ·· ·· ·· ·· ·· ·· ·· ·· ··
L1 18 (5%) 6 (2%) ·· 2 (6%) 0 0 0 2 (8%) 4 (2%) 1 (1%) 0 3 (8%)
L2 79 (23%) 56 (23%) ·· 7 (20%) 3 (38%) 1 (50%) 0 3 (13%) 49 (24%) 23 (16%) 8 (33%) 18 (47%)
L3 15 (4%) 3 (1%) ·· 0 0 0 0 0 3 (1%) 2 (1%) 1 (4%) 0
L4 225 (66%) 178 (73%) ·· 26 (74%) 5 (63%) 1 (50%) 1 (100%) 19 (79%) 152 (73%) 120 (82%) 15 (63%) 17 (45%)
L5 1 (<1%) 0 ·· 0 0 0 0 0 0 0 0 0
L6 1 (<1%) 0 ·· 0 0 0 0 0 0 0 0 0
Country ·· ·· <0·0003 ·· ·· ·· ·· ·· ·· ·· ··
Côte d’Ivoire 46 (14%) 48 (20%) ·· 5 (14%) 2 (25%) 0 1 (100%) 2 (8%) 43 (21%) 39 (27%) 3 (13%) 1 (3%)
Democratic 
Republic of the 
Congo
29 (9%) 30 (12%) ·· 1 (3%) 0 0 0 1 (4%) 29 (14%) 19 (13%) 8 (33%) 2 (5%)
Kenya 21 (6%) 7 (3%) ·· 1 (3%) 1 (13%) 0 0 0 6 (3%) 5 (3%) 0 1 (3%)
Nigeria 19 (6%) 34 (14%) ·· 6 (17%) 0 0 0 6 (25%) 28 (13%) 20 (14%) 4 (17%) 4 (11%)
Peru 57 (17%) 36 (15%) ·· 2 (6%) 2 (25%) 0 0 0 34 (16%) 28 (19%) 2 (8%) 4 (11%)
South Africa 111 (33%) 61 (25%) ·· 15 (43%) 0 1 (50%) 0 14 (58%) 46 (22%) 28 (19%) 7 (29%) 11 (29%)
Thailand 56 (17%) 27 (11%) ·· 5 (14%) 3 (38%) 1 (50%) 0 1 (4%) 22 (11%) 7 (5%) 0 15 (39%)
History of 
tuberculosis
·· ·· <0·0001 ·· ·· ·· ·· ·· ·· ·· ·· ··
No 269 (79%) 104 (43%) ·· 13 (37%) 7 (88%) 1 (50%) 1 (100%) 4 (17%) 91 (44%) 56 (38%) 5 (21%) 30 (79%)
Yes 70 (21%) 139 (57%) ·· 22 (63%) 1 (13%) 1 (50%) 0 20 (83%) 117 (56%) 90 (62%) 19 (79%) 8 (21%)
Treatment outcomes ·· ·· <0·0001 ·· ·· ·· ·· ·· ·· ·· ·· ··
Success 248 (73%) 129 (53%) ·· 16 (46%) 5 (63%) 0 1 (100%) 10 (42%) 113 (54%) 76 (52%) 11 (46%) 26 (68%)
Mortality 19 (6%) 45 (19%) ·· 6 (17%) 1 (13%) 1 (50%) 0 4 (17%) 39 (19%) 24 (16%) 9 (38%) 6 (16%)
Treatment failure 11 (3%) 10 (4%) ·· 3 (9%) 0 1 (50%) 0 2 (8%) 7 (3%) 5 (3%) 2 (8%) 0
Lost to follow-up 26 (8%) 29 (12%) ·· 5 (14%) 0 0 0 5 (21%) 24 (12%) 22 (15%) 0 2 (5%)
Transfer 13 (4%) 15 (6%) 2 (6%) 0 0 0 2 (8%) 13 (6%) 10 (7%) 2 (8%) 1 (3%)
Ongoing, unknown 22 (6%) 15 (6%) ·· 3 (9%) 2 (25%) 0 0 1 (4%) 12 (6%) 9 (6%) 0 3 (8%)
Sputum ·· ·· 0·089 ·· ·· ·· ·· ·· ·· ·· ·· ··
Positive 264 (78%) 205 (84%) ·· 25 (71%) 7 (88%) 1 (50%) 1 (100%) 16 (67%) 180 (87%) 129 (88%) 17 (71%) 34 (89%)
Negative 68 (20%) 36 (15%) ·· 10 (29%) 1 (13%) 1 (50%) 0 8 (33%) 26 (13%) 17 (12%) 6 (25%) 3 (8%)
Data are n (%) or median (IQR). p values show the difference between pan-susceptible and any resistance, obtained with the χ² test (L5 and L6 were excluded and for age the t test was used). The category other 
included the following drug resistances: cycloserine (n=1); ethionamide (n=5); streptomycin (n=9); ethambutol and rifampicin (n=1); ethambutol and streptomycin (n=1); isoniazid and ethionamide (n=14); 
isoniazid and pyrazinamide (n=1); isoniazid and streptomycin (n=1); ethambutol, isoniazid, and streptomycin (n=1); isoniazid, ethionamide, and streptomycin (n=1); rifampicin, pyrazinamide, streptomycin, and 
ethionamide (n=1); isoniazid, levofloxacin, moxifloxacin, ofloxacin, para-aminosalicylic acid, and ciprofloxacin (n=1); ethambutol, rifampicin, levofloxacin, moxifloxacin, ofloxacin, ciprofloxacin, and streptomycin 
(n=1). XDR=extensively drug-resistant. Due to rounding, some group percentage totals are more than 100%. 
Table 1: Patient characteristics by resistance profiles obtained by whole-genome sequencing
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DNA quality, or failures in the library preparation 
(appendix p 2). We therefore included 582 patients with 
tuberculosis, 406 (70%) from Africa, 93 (16%) from Latin 
America, and 83 (14%) from Asia. 172 (30%) patients came 
from South Africa, 94 (16%) from Côte d’Ivoire, 93 (16%) 
from Peru, 83 (14%) from Thailand, 59 (10%) from 
Democratic Republic of the Congo, 53 (9%) from Nigeria, 
and 28 (5%) from Kenya (table 1). The median age was 
33 years (IQR 27–43), 225 (39%) were women, and 
247 (42%) were HIV-positive. Six M tuberculosis lineages 
were represented: 24 (4%) cases of L1, 135 (23%) L2, 
18 (3%) L3, 403 (69%) L4, one (<1%) L5, and one (<1%) L6.
Based on WGS, 339 (58%) isolates were pan-susceptible 
and 35 (6%) were monoresistant: 24 rifampicin, eight 
isoniazid, two pyrazinamide, and one ethambutol mono-
resistant isolates. There were 208 (36%) polyresistant 
isolates, including 146 (25%) MDR, 24 (4%) pre-XDR or 
XDR isolates, and 38 (7%) other types of polyresistances 
(table 1; figure 1). Among the 24 patients with pre-XDR or 
XDR, nine had resistance to fluoroquinolones, six to 
injectable drugs, and nine to both.
Local drug susceptibility testing results were based on the 
molecular Xpert MTB/RIF test system, line probe assays, 
and culture-based phenotypic tests, or a combination of 
these methods (table 2). Among the 582 isolates, 130 (22%) 
of 582 had discordant drug resistance results when 
comparing local drug susceptibility testing with WGS. 
65 (11%) discordant drug resistance results potentially led 
to inappropriate treatment of patients with tuberculosis 
(table 2). We then looked at the regimens prescribed to 
patients. For six patients, we had no treatment information. 
Of 576 patients with known treatment, we observed that 
overall 86 (15%) of 576 patients received inappropriate 
treatment according to WGS results and WHO treatment 
guidelines: 67 (12%) of 576 patients were undertreated, and 
19 (3%) were overtreated. Consequently, 490 (85%) patients 
were appropriately treated.
The agreement between local drug susceptibility 
testing and WGS was 80% for pan-susceptible, 8% for 
monoresistant, 66% for MDR, and 33% for pre-XDR or 
XDR tuberculosis (figure 1). Agreement of local drug 
susceptibility testing and WGS for rifampicin resistance 
was 86% and it was 65% for isoniazid resistance. 
Rifampicin resistance was, in contrast to other drug 
resistance, more frequently diagnosed with local drug 
susceptibility testing than with WGS (figure 1). Only 
three sites tested for drugs other than rifampicin and 
isoniazid. Two sites tested for streptomycin, two for 
fluoro quinolones, and two for injectable drugs. One 
site tested for pyrazinamide and one site for ethambutol. 
Resistance to pyrazinamide, cycloserine, ethambutol, 
linezolid, bedaquiline, clofazimine, and delamanid was 
not tested at any site. WGS did not identify any 
resistance to bedaquiline, clofazimine, or delamanid 
(appendix p 8).
We excluded 52 (9%) of 582 patients from the 
mortality analyses due to missing data (appendix p 2). 
Based on WGS, the isolates of 310 (58%) of 530 patients 
were pan-susceptible, 32 (6%) monoresistant, 131 (25%) 
MDR, 23 (4%) pre-XDR or XDR, and 34 (6%) other 
polyresistances. Among the 530 patients, 121 (23%) 
had discordant drug susceptibility testing results. 
For 29 (66%) of 44 patients, underdiagnosis of 
drug resistance potentially led to undertreatment, and 
for 28 (36%) of 77, overdiagnosis potentially led 
to overtreatment. During treatment, 63 (12%) of 
530 patients died (table 3). Mortality was 6% (18 of 310) 
in patients with pan-susceptible tuber culosis, 19% (six 
of 32) in patients with monoresistant tuberculosis, and 
18% (24 of 131) in patients with MDR tuberculosis. 
Patients with pre-XDR or XDR tuberculosis had a 
mortality of 39% (nine of 23; figure 2A). Overall, 
mortality ranged from 6% (16 of 267) among patients 
with pan-susceptible strains and concordant diagnosis 
to 47% (seven of 15) among patients with pre-XDR or 
XDR tuberculosis and a discordant diagnosis potentially 
leading to undertreatment (table 3). In patients with a 
discordant diagnosis potentially leading to undert-
reatment, mortality was 28% (eight of 29), and in 
patients with a discordant diagnosis potentially leading 
to overtreatment, it was 4% (one of 28; figure 2B). 
Mortality ranged from 6% (17 of 293) in patients with 













































Figure 1: Distribution of diagnosed drug resistance between whole-genome 
sequencing and local drug susceptibility testing
The categories include pan-susceptible, monoresistant (any monoresistance), 
multidrug-resistant, pre-XDR or XDR, any isoniazid-resistant, or any 
rifampicin-resistant tuberculosis. Due to rounding, some group percentage totals are 
more than 100%. XDR=extensively drug-resistant.
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Drug resistance n (%) Local drug susceptibility test diagnosis method
Based on whole-genome 
sequencing




Concordance between resistance patterns
Total ·· 452 (100%) 242/452 (54%) 195/452 (43%) 60/452 (13%) 102/452 (23%)
Pan-susceptible Pan-susceptible 293 (65%) 196 139 49 53
Monoresistant (3 isoniazid, 
2 rifampicin)
3 isoniazid, 2 rifampicin 5 (1%) 0 4 1 0
MDR MDR 138 (31%) 45 44 8 44
Pre-XDR or XDR Pre-XDR or XDR 9 (2%) 1 1 2 5
Other (7 streptomycin) 7 streptomycin 7 (2%) 0 7 0 0
Discordance between resistance patterns
Total ·· 130 (100%) 35/130 (27%) 55/130 (42%) 9/130 (7%) 46/130 (35%)
Potentially leading to 
undertreatment
·· 34 (26%) 17/130 (13%) 12/130 (9%) 1/130 (1%) 1/130 (1%)
Pan-susceptible ·· 0 0 0 0 0
Monoresistant (3 isoniazid) 3 pan-susceptible 3 (2%) 2 1 0 0
MDR 3 pan-susceptible, 
1 streptomycin-ethambutol
4 (3%) 2 1 0 1
Pre-XDR or XDR 15 MDR 15 (12%) 5 6 0 4




12 pan-susceptible 12 (9%) 8 4 0 0
Potentially leading to 
overtreatment
·· 31 (24%) 3/130 (2%) 12/130 (9%) 2/130 (2%) 14/130 (11%)
Pan-susceptible 1 isoniazid, 18 MDR, 
4 rifampicin
23 (18%) 3 9 2 9
Monoresistant (2 isoniazid) 2 MDR 2 (2%) 0 2 0 0
MDR 3 Pre-XDR or XDR 3 (2%) 0 0 0 3
Pre-XDR or XDR ·· 0 0 0 0 0




3 MDR 3 (2%) 0 1 0 2
Other discordance ·· 65 (50%) 15/130 (12%) 31/130 (9%) 6/130 (1%) 27/130 (4%)
Pan-susceptible 20 ethambutol, 
1 monoresistant†, 
2 streptomycin
23 (18%) 2 20 0 1
Monoresistant (1 ethambutol, 
2 pyrazinamide, 22 rifampicin)
1 pan-susceptible, 2 
pan-susceptible, 22 MDR
25 (19%) 6 1 1 20
MDR 1 rifampicin 1 (1%) 0 0 1 0



























16 (12%) 7 10 5 6
MDR=multidrug-resistant. XDR=extensively drug-resistant. *Rifampicin resistance diagnosed with Xpert MTB/RIF was classified as MDR. †Exact monoresistance is not known. 
Table 2: Drug resistance results from whole-genome sequencing and local testing by diagnosis concordance and potential consequences for treatment
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guidelines to 32% (19 of 60) in under treated patients 
and 6% (one of 17) in patients who were overtreated 
(figure 2C).
In the multivariable logistic regression, resistance to 
any of the anti-tuberculosis drugs was associated 
with higher mortality (figure 3). The adjusted odds 
ratio (OR) was 5·58 (95% CI 2·86–10·90). The association 
with mortality became stronger with a higher degree 
of drug resistance. Compared with pan-susceptible 
tuberculosis, the adjusted OR for monoresistant was 5·88 
(95% CI 1·92–17·98), for MDR was 5·55 (2·53–12·20), 
and for pre-XDR or XDR tuberculosis was 23·03 
(7·16–74·05; figure 3). The adjusted OR for mortality 
during tuberculosis treatment was 4·07 (95% CI 
1·58–10·47) in patients with a diagnosis potentially 
leading to undertreatment, and 0·29 (0·04–2·19) in the 
case of a diagnosis potentially leading to overtreatment, 
compared with patients with appropriate treatment 
(figure 3). Overall, 77 (15%) of 530 patients received 
inappropriate treatment based on WGS drug resistance 
results and WHO guidelines (appendix p 7). 60 (11%) of 
530 patients were undertreated, and 17 (3%) of 530 were 
overtreated. The OR for mortality for undertreatment 
was 4·92 (95% CI 2·47–9·78), and for overtreatment 
was 0·52 (0·07–4·20), compared with patients receiving 
appropriate treatment (figure 3). In a sensitivity analysis, 
we showed that mortality among undertreated patients 
remained higher than among appropriately treated 
patients after excluding patients with pre-XDR or XDR 
tuberculosis (adjusted OR 5·97 [95% CI 2·58–13·80]). 
The unadjusted covariate ORs for mortality during 
tuberculosis treatment are shown in the appendix (p 13). 
The sensitivity analysis of the logistic regression models 
using different variant frequency cutoffs (≥0% and 100%) 
produced similar results (appendix pp 3–4). When 
restricting the analysis to drug resistances that could be 
diagnosed at sites, again similar results were obtained 
(appendix p 5).
Discussion
In this multicentre cohort study, we compared drug 
resistance predicted by WGS with the results from local 
drug susceptibility testing in seven countries with a high 
burden of tuberculosis. We examined mortality by drug 
resistance predicted by WGS, and by concordance or 
discordance with local diagnosis and the appropriateness 
of treatment. We found that the diagnosis was discordant 
between local drug resistance results and WGS in about 
one in five patients. The agreement between local and 
centralised WGS was the highest for rifampicin and 
isoniazid, but low for other drugs. Of note, resistance to 
streptomycin, para-aminosalicylic acid, pyrazinamide, 
cycloserine, ethionamide, ethambutol, fluoroquinolones, 
and injectable drugs was rarely investigated locally. 
Mortality during treatment ranged from 6% among 
patients with pan-susceptible strains and concordant 
results between WGS and local drug resistance testing to 
47% among patients with pre-XDR or XDR tuberculosis 
and discordant results.
To our knowledge, this is the first study to compare 
the results from drug susceptibility testing in 
real-world settings in high-burden countries with WGS 
and to examine the effect of discordant resistance results 
on mortality. In a previous analysis of this cohort, we 
Total Concordant with 
diagnosis at sites
Discordant with diagnosis at sites






Resistance based on whole-genome 
sequencing
63/530 (12%) 44/409 (11%) 19/121 (16%) 8/30 (27%) 1/28 (4%) 10/63 (16%)
Pan-susceptible 18/310 (6%) 16/267 (6%) 2/43 (5%) 0/0 0/20 2/23 (9%)
Any resistance 45/220 (20%) 28/142 (20%) 17/78 (22%) 8/30 (27%) 1/8 (13%) 8/40 (20%)
Monoresistance 6/32 (19%) 2/4 (50%) 4/28 (14%) 0/1 0/2 4/25 (16%)
Isoniazid 1/6 (17%) 1/3 (33%) 0/3 0/1 0/2 0/0
Pyrazinamide 1/2 (50%) 0/0 1/2 (50%) 0/0 0/0 1/2 (50%)
Ethambutol 0/1 0/0 0/1 0/0 0/0 0/1
Rifampicin 4/23 (17%) 1/1 (100%) 3/22 (14%) 0/0 0/0 3/22 (14%)
Polyresistance 39/188 (21%) 26/138 (19%) 13/50 (26%) 8/29 (28%) 1/6 (17%) 4/15 (27%)
Multidrug resistance 24/131 (18%) 23/123 (19%) 1/8 (13%) 1/4 (25%) 0/3 0/1
Pre-XDR or XDR 9/23 (39%) 2/8 (25%) 7/15 (47%) 7/15 (47%) 0/0 0/0
Other 6/34 (18%) 1/7 (14%) 5/27 (19%) 0/9 1/3 (33%) 4/15 (27%)
Analysis based on 530 patients with complete data. The category other discordance includes the following drug resistances: cycloserine (n=1); ethionamide (n=5); 
streptomycin (n=9); ethambutol and rifampicin (n=1); isoniazid and ethionamide (n=12); isoniazid and pyrazinamide (n=1); ethambutol, isoniazid, and streptomycin (n=1); 
ethambutol, isoniazid, and streptomycin (n=1); rifampicin, pyrazinamide, streptomycin, and ethionamide (n=1); isoniazid, levofloxacin, moxifloxacin, ofloxacin, 
para-aminosalicylic acid, and ciprofloxacin (n=1); and ethambutol, rifampicin, levofloxacin, moxifloxacin, ofloxacin, ciprofloxacin, and streptomycin (n=1). XDR=extensively 
drug-resistant.
Table 3: Mortality by concordance of local diagnosis and whole-genome sequencing
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compared the results from local drug susceptibility 
testing with those obtained at the Swiss National Center 
for Mycobacteria for six drugs.9 In the present study, we 
used a well established bioinformatics pipeline and its 
corresponding database to analyse the WGS data.10 The 
analysis covered 19 anti-tuberculosis drugs, including 
streptomycin, kanamycin, pyrazinamide, ethionamide, 
ethambutol, and levofloxacin, as well as newer drugs. 
Specifically, we were able to detect more single-drug 
resistance with WGS than with phenotypic drug 
susceptibility testing.
Rapid and accurate diagnosis, prompt and appropriate 
treatment, and the control of airborne infection are key 
strategies to prevent drug-resistant tuberculosis.23 Routine 
testing at sites focused mainly on the identification of 
rifampicin and isoniazid resistance used to diagnose 
MDR tuberculosis and did not address the efficacy of 
other drugs. Also, isoniazid monoresistance would 
typically be missed if drug susceptibility testing relies on 
the Xpert MTB/RIF system, which could lead to the 
undertreatment of some patients. Furthermore, culture-
based drug susceptibility testing is challenging for several 
drugs—eg, pyrazinamide, ethionamide, and ethambutol—
due to poor drug solubility.11,24 Yet, pyrazinamide is 
essential for shortening tuberculosis therapy, and 
resistance to pyrazinamide is associated with worse 
outcomes.23 However, pyrazinamide resistance testing is 
often unavailable. Only one site could test pyrazinamide 
resistance in our study.
WGS has the potential to predict resistance profiles for 
most anti-tuberculosis drugs without the need for time-
consuming phenotypic drug susceptibility testing.10–12,19 
WGS provides simultaneous and comprehensive 
information on relevant mutations conferring resistance 
to first-line and second-line drugs, anywhere in the 
genome. By contrast, targeted sequencing only identifies 
mutations in a priori defined regions covered by the 
amplifications. WGS allows effective individualised 
treatment, and thus reduces the risk of propagating drug 
resistance. Ineffective treatment could lead to the 
acquisition of additional drug resistance and increases 
the risk of transmitting drug-resistant strains.23 These 
considerations support the use of WGS to replace the 
current drug susceptibility testing methods, which cover 
only a limited number of drugs.
The broader range of drug resistance captured by WGS 
explains some of the discordant results found in this study; 
however, restricting the analysis of discordances between 
drug resistance diagnosed locally and by WGS to the most 
clinically relevant WHO categories of drug resistance will 
have minimised this effect.13 Thus, discordant results 
potentially leading to inappropriate treatment were mainly 
due to important drug resistance not captured with the 
available local tests at sites, rather than to a wider range of 
drug resistances captured by WGS. The detection of drug 
resistance is also influenced by the type of sample collected, 
and the methods used for culturing, DNA extraction and 
sequencing, and the pipeline used to analyse the 
sequences.25 The pipeline used to analyse the sequences 
was determined by a 90% or greater variant frequency 
cutoff, the robustness of the TBprofiler pipeline, and its 
coverage of all relevant resistance-conferring mutations. 
Our sensitivity analysis showed that the cutoff for variant 
frequency had little effect on results.
For new drugs, most resistance-conferring mutations 
are unknown at the time of introduction, and relevant 
drug resistance mechanisms become apparent only 
when the mutation becomes established in the 
Figure 2: Mortality according to drug resistance, concordance of diagnosis, 
and treatment appropriateness
Mortality data are shown based on drug resistance (A), concordance of 
diagnosis (B), and treatment appropriateness (C). Appropriateness was 
considered according to WHO guidelines (appendix pp 6–7). Error bars are SEs. 
Analysis based on 530 patients with complete data. Mortality was calculated by 
dividing deaths by the number of patients in the respective category. 
MDR=multidrug-resistant. XDR=extensively drug-resistant.
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population. The TBprofiler database is continuously 
updated with newly identified resistance-conferring 
mutations, such as bedaquiline in 2013 and dalamanid 
in 2014. Yet, the accuracy of the prediction of phenotypic 
resistance by molecular markers varies by drugs, 
depending on the molecular mechanisms involved and 
the evidence generated so far. We showed that the 
identification of drug-resistance-conferring mutations 
predicted phenotypic resistance to rifampicin better 
than to ethambutol.11 Discrepancies in results between 
local drug susceptibility testing and WGS might also 
be explained by mixed infections, heteroresistance, 
minority resistant populations, or methodological 
differences,25–27 which can lead to uncertainties in 
treatment decisions.28 Of note, overtreatment did not 
increase mortality, but the analysis was based on few 
patients (n=28) and should be interpreted with caution. 
Anti-tuberculosis drugs, especially second-line drugs, 
can cause serious side-effects, which can lead to 
treatment interruption, and failure, or acquired drug 
resistance, and should therefore only be used when 
needed.29
Our study has several limitations. We sampled eligible 
patients within strata defined by drug resistance and HIV 
infection, and therefore, could not estimate the incidence 
or prevalence of drug-resistant tuberculosis in patients 
who were HIV-coinfected or HIV-negative. Also, we could 
not evaluate differences in drug resistance between 
M tuberculosis lineages because the sample size was small 
for several lineages. Our analysis is mainly based on L2 
and L4 strains, as expected from the geographical 
distribution of these lineages.30 Further, we sequenced 
strains before treatment and thus could not diagnose 
potentially acquired drug resistance, which might 
influence treatment outcomes. Finally, this study reflects 
the years 2013–16. Since then, the availability of drug 
resistance tests has increased (appendix p 14). For example, 
the MTBDRsl assay (Hain Lifescience, Nehren, Germany), 
a line probe assay for the detection of pre-XDR or XDR, is 
now available at four sites. However, three of the seven 
sites still have no access to rapid molecular tests to 
diagnose resistance to second-line drugs. In general, there 
were only a few changes in the drug resistances that are 
tested routinely between the study period and 2020 
(appendix p 14).
Treatment guidelines also changed over the study 
period. In 2013, WHO published an interim policy 
guideline on bedaquiline, and in 2014 on delamanid in 
the treatment of MDR tuberculosis.31,32 In our study, 
patients were rarely given newer drugs such as 
bedaquiline or delamanid. In 2020, only South Africa 
included bedaquiline in their short and long MDR 
tuberculosis regimens. By contrast, the other sites are 
still using the so-called Bangladesh regimen (ie, a 
standardised short course MDR tuberculosis treatment 
regimen of 9–12 months), although guidelines will 
probably change in the near future. Identifying the 
emergence of resistance to recently introduced drugs will 
be crucial alongside the roll-out of new regimens.33
Our study shows that treatment strategies guided by 
comprehensive drug resistance data are likely to save lives. 
Our results thus support WHO’s call for an accurate point-
of-care test based on WGS that can be done directly from 
sputum samples.34 Such tests would allow rapid diagnosis 
and efficient, individual-based treatment of drug-resistant 
tuberculosis.35 Test systems performing WGS on sputum 
samples, using new laboratory and bioinformatics pipelines 
are in development. High-burden countries should 
consider building central, high-throughput sequencing 
capacities.36 The establishment of a trustworthy, widely 
accepted drug resistance database similar to the Stanford 
HIV drug resistance database will be essential in this 
context.37 Finally, we support the call for clinical trials 
evaluating the safety, efficacy, and tolerability of new drugs 
and drug susceptibility testing strategies for drug-resistant 
tuberculosis.23,29 The role of new drugs like bedaquiline, 
delamanid, and pretomanid in regimens with fewer, 
more effective, and safer drugs needs to be evaluated.23 
Future studies should also examine treatment duration and 
adherence.23 The duration of the intensive and continuation 
phases of tuberculosis treatment and treatment adherence 
are crucial for efficient therapy.
In conclusion, our study shows that both the accuracy 
of drug susceptibility testing in routine care, and the 
access to testing for resistance for several essential drugs 
is limited in high-burden tuberculosis countries, which 
leads to inappropriate treatment, and contributes to 
Figure 3: Logistic regression models to assess the effect of any drug resistance, drug resistance categories, 
diagnosis discordance, and treatment appropriateness on mortality
The models were adjusted for sex, age, HIV status, history of tuberculosis, and sputum microscopy, and country of 
participating site was included as random effect on the intercept. Appropriateness was considered according to 
WHO guidelines (appendix pp 6–7). XDR=extensively drug-resistant.
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higher mortality. Our results support the role of WGS to 
improve the management of drug-resistant tuberculosis 
in high-burden settings.
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